Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

Schönherr, H., Ayaz, P., Taylor, A. M., Casaletto, J. B., Touré, B. B., Moustakas, D. T., Hudson, B. M., Valverde, R., Zhao, S., O’Hearn, P. J., Foster, L., Sharon, D. A., Garfinkle, S., Giordanetto, F., Lescarbeau, A., Kurukulasuriya, R., Gerami-Moayed, N., Maglic, D., Bruderek, K., … Bergstrom, D. A. (2024). Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences, 121(6). https://doi.org/10.1073/pnas.2317756121
Authors:
Heike Schönherr
Pelin Ayaz
Alexander M Taylor
Jessica B Casaletto
B Barry Touré
Demetri T Moustakas
Brandi M Hudson
Roberto Valverde
Songping Zhao
Patrick J O'Hearn
Lindsey Foster
Dina A Sharon
Sam Garfinkle
Fabrizio Giordanetto
André Lescarbeau
Ravi Kurukulasuriya
Nastaran Gerami-Moayed
Dejan Maglic
Kamil Bruderek
Gaauri Naik
Hakan Gunaydin
Mary M Mader
Alessandro A Boezio
Thomas H McLean
Rongfeng Chen
Yanxia Wang
David E Shaw
James Watters
Donald A Bergstrom
Affiliated Authors:
David E Shaw
Author Keywords:
fgfr2 inhibitor
cholangiocarcinoma
molecular dynamics simulation
motion-based drug design
Publication Type:
Article
Unique ID:
10.1073/pnas.2317756121
PMID:
Publication Date:
Data Source:
PubMed

Record Created: